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Streptococcus pneumoniae (S. pneumoniae) is one of the leading causes of invasive bacterial disease in 
children. In 2000 it contributed to 11% of deaths in children aged 1-59 months (1). Invasive pneumococcal 
disease can result in septicemia, meningitis and pneumonia. Two pneumococcal glycoconjugate vaccines were 
introduced in 2000 and 2010 in the USA. Deaths due to the serotypes included in these vaccines in children 
under 5 have fallen from 183 cases per 100,000 in 1998, to 11 per 100,000 in 2015.  
 
The current gold standard glycoconjugate vaccine for immunization is Prevenar 13. It is the leading global 
vaccine product generating over $6 billion dollars in revenue in 2016. The cost per dose in the USA is over $100 
with a total of four doses required in young children. Due to the complex manufacturing process for the vaccine 
the expense of the dose is driven up. The process involves separate fermentations for the thirteen serotypes 
and for the carrier protein component. Subsequent to this are stripping, purification, activation and chemical 
conjugation steps to make the vaccine and another series of purifications to make the final formulation. The 
chemical conjugation step requires personnel with a high level of experience and intricate knowledge of the 
reaction and is a limiting factor for new low income country manufacturers in entering this market. 
 
The advent of Protein Glycan Coupling Technology (PGCT) has been an important development.  This plasmid-
based technology is able to produce glycoconjugate vaccines intracellularly in E. coli (2). As a result, there is no 
need for the chemical conjugation steps, meaning personnel do not need to have the niche skills currently 
required. Furthermore, the number of purification steps during the process are also reduced. 
 
E. coli cells have been engineered with PGCT to produce a glycoconjugate vaccine of Serotype 4 of S. 
pneumoniae. Using this cell line, transition of E. coli growth from shake flasks into small scale bioreactors has 
been performed. Results show cell biomass is increased in bioreactors and volumetric productivity of cells is 
improved. It has also become apparent that any changes to the system need to be carefully considered. For 
example, comparison of two different proteins in this system has found one is more amenable to glycosylation 
indicating that choice of protein will have an effect on glycoconjugate production. Overall these experiments 
have demonstrated the scalability of PGCT and has laid the foundation for future optimization of the system.  
 
The work presented here is using S. pneumoniae in a platform process for the production of pneumococcal 
conjugate vaccines. Here a new vaccine production technology is being optimized and scaled to increase 
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